SCH 57790: a novel M2 receptor selective antagonist. 1999

J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
Department of Chemical Research, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.

As a decrease in cholinergic neurons has been observed in Alzheimer's Disease (AD), therapeutic approaches to AD include inhibition of acetylcholinesterase to increase acetylcholine levels. Evidence suggests that acetylcholine release in the CNS is modulated by negative feedback via presynaptic M2 receptors, blockade of which should provide another means of increasing acetylcholine release. Structure-activity studies of [4-(phenylsulfonyl)phenyl]methylpiperazines led to the synthesis of 4-cyclohexyl-alpha-[4-[[4-methoxyphenyl]sulfinyl]-phenyl]-1-piperazin eacetonitrile. This compound, SCH 57790, binds to cloned human M2 receptors expressed in CHO cells with an affinity of 2.78 nM; the affinity at M1 receptors is 40-fold lower. SCH 57790 is an antagonist at M2 receptors expressed in CHO cells, as the compound blocks the inhibition of adenylyl cyclase activity mediated by the muscarinic agonist oxotremorine. This compound should be useful in assessing the potential of M2 receptor blockade for enhancement of cognition.

UI MeSH Term Description Entries
D010095 Oxotremorine A non-hydrolyzed muscarinic agonist used as a research tool. Oxytremorine
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011813 Quinuclidinyl Benzilate A high-affinity muscarinic antagonist commonly used as a tool in animal and tissue studies. Benzilate, Quinuclidinyl
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D005576 Colforsin Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland. Coleonol,Forskolin,N,N-Dimethyl-beta-alanine-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho(2,1-b)pyran-6-yl Ester HCl,NKH 477,NKH-477,NKH477
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000109 Acetylcholine A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. 2-(Acetyloxy)-N,N,N-trimethylethanaminium,Acetilcolina Cusi,Acetylcholine Bromide,Acetylcholine Chloride,Acetylcholine Fluoride,Acetylcholine Hydroxide,Acetylcholine Iodide,Acetylcholine L-Tartrate,Acetylcholine Perchlorate,Acetylcholine Picrate,Acetylcholine Picrate (1:1),Acetylcholine Sulfate (1:1),Bromoacetylcholine,Chloroacetylcholine,Miochol,Acetylcholine L Tartrate,Bromide, Acetylcholine,Cusi, Acetilcolina,Fluoride, Acetylcholine,Hydroxide, Acetylcholine,Iodide, Acetylcholine,L-Tartrate, Acetylcholine,Perchlorate, Acetylcholine
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000262 Adenylyl Cyclases Enzymes of the lyase class that catalyze the formation of CYCLIC AMP and pyrophosphate from ATP. Adenyl Cyclase,Adenylate Cyclase,3',5'-cyclic AMP Synthetase,Adenylyl Cyclase,3',5' cyclic AMP Synthetase,AMP Synthetase, 3',5'-cyclic,Cyclase, Adenyl,Cyclase, Adenylate,Cyclase, Adenylyl,Cyclases, Adenylyl,Synthetase, 3',5'-cyclic AMP

Related Publications

J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
September 2009, Future cardiology,
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
November 1995, European journal of pharmacology,
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
December 2020, Bioorganic & medicinal chemistry letters,
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
January 1992, Psychopharmacology,
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
January 2001, CNS drug reviews,
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
April 2001, Life sciences,
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
May 1985, Life sciences,
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
April 1988, European journal of pharmacology,
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
April 1991, Lancet (London, England),
J E Lachowicz, and D Lowe, and R A Duffy, and V Ruperto, and L A Taylor, and H Guzik, and J Brown, and J G Berger, and M Tice, and R McQuade, and J Kozlowski, and J Clader, and C D Strader, and N Murgolo
September 1993, European journal of pharmacology,
Copied contents to your clipboard!